[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][=C][C][=C][Branch2][Branch1][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][N][C][=Branch2][Ring2][O][=C][C][=Branch1][Ring2][=N][Ring1][Branch1][C][=N][C][=C][Branch2][Ring1][N][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][C][C@@][Branch1][=Branch1][C][=Branch1][C][=O][N][Branch1][=Branch2][C][Branch1][C][F][Branch1][C][F][F][O][F][C][=N][O][C][=C][Ring1][Branch1][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable stimulator of soluble guanylate cyclase (sGC), with potential anti-inflammatory and vasodilating activities.  Upon oral administration, olinciguat targets, allosterically binds to and enhances the nitric oxide (NO)-dependent catalytic activity of sGC. This enhances NO-sGC signaling and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This enhances NO/cGMP-mediated muscle relaxation, suppresses leukocyte-endothelial interactions and promotes vascular anti-inflammatory effects. The NO/sGC/cGMP signaling pathway plays an important role in vasodilation, blood flow and inflammatory processes. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to NO binding to heme."}]